Martin Perry, MBChB, BSc, MMEd, FRCP, clinical medical director for the National Health Service in Greater Glasgow and Clyde, Scotland, explains frontline care with biosimilars during COVID-19.
The Center for Biosimilars® spoke with Martin Perry, MBChB, BSc, MMEd, FRCP, Clinical Medical Director for the National Health Service (NHS) in the Greater Glasgow and Clyde region of Scotland about biosimilar savings and access during COVID-19. Perry was a presenter on the topic during the recent Terrapinn Festival of Biologics meeting in Basel, Switzerland.
Perry oversaw a COVID-19 ward and during this talk with The Center for Biosimilars® Senior Editor Tony Hagen, he explains the challenges of providing treatment for patients. He also sheds light on the United Kingdom's unique system of biosimilar choice and pricing. Access to biosimilars has broadened in the United Kingdom, partly due to the lower cost of these agents; but overall spending on biologics and specialty drugs is on the increase there, as in the United States.
Perry also addresses switching patients from reference products to biosimilars and patient acceptance. Nocebo, or the potential for patients with poor attitudes toward biosimilars to influence their own outcomes, is a very real concern, Perry explains, underscoring the need for strong educational efforts to support biosimilar use.
Brexit, or the United Kingdom's separation from the economic apron strings of the European Union, is well along since the beginning of 2021, and this has resulted in "no notable difference" in biosimilar supply, Perry reports.
The UK continues to get a handle on the COVID-19 pandemic, and its most recent spike in cases is on the wane; and in the Glasgow/Clyde area the infection rate hasn't been as serious as in the Southeast (London), partly because residents have been more adherent to mask mandates, Perry speculates. Overall, the United Kingdom has seen 1 in 7 residents infected with COVID-19, according to an ongoing New York Times analysis.
Perry says many UK residents are now coping with lingering complications of COVID-19, and the NHS is working to address these issues while seeking to reestablish normal services across the health care spectrum. "Currently, we're in a quieter phase in comparison with other stages" of the pandemic, he says.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.